Victor I Lyamichev

This inventor holds 97 USPTO granted patents and 5 published patent applications, plus 10 CIPO patents and 18 EPO patents, primarily in Nucleic Acid Detection (CPC class C12Q1-68). Top assignees: Third Wave Technologies, Inc., Roche Sequencing Solutions, Inc., Hoffmann-La Roche Inc.. Active years: 1995-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Victor I Lyamichev. Retrieved from https://idiyas.com/inventor/victor-i-lyamichev

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 97 (Patent Applications = 5)

% Patents Active = 61.9

CIPO Patents = 10 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 20)

Average Co-Inventor Count = 4.4

ph-index = 44

Forward Citations = 5,619(Granted Patents)

Forward Citations (Not Self Cited) = 4,987(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Company Filing History:

81 out of 102

Third Wave Technologies, Inc.

patents

10 out of 299

Roche Sequencing Solutions, Inc.

patents

2 out of 5,026

Hoffmann-La Roche Inc.

patents

4. 2 out of 2,220

Northwestern University

patents

5. 2 out of 4,243

Wisconsin Alumni Research Foundation

Roche Nimblegen, Inc.

patents

where one patent can have more than one assignee

Years Active: 1995-2026

Loading Chart...

Areas of Expertise:

Peptide Libraries

Nucleic Acid Detection

Transglutaminase

BACE1 Inhibitor Peptides

RNA Detection Assays

Oligonucleotide Modification

Invasive Cleavage

Solid-Phase Reactions

Target Quantification

Enzyme Cleavage Methods

Charge Tags

Nucleic Acid Amplification

97 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595591 - PEPTIDE LIBRARIES HAVING ENHANCED SUBSEQUENCE DIVERSITY AND METHODS FOR USE THEREOF (2026-04-07),

2. 11583575 - MHC-bound peptide arrays and methods of use thereof (2023-02-21),

3. 11280791 - System and method for identification and characterization of transglutaminase species (2022-03-22),

4. 11268120 - Identification of transglutaminase substrates and uses therefor (2022-03-08),

5. 11054425 - System and method for identification and characterization of transglutaminase species (2021-07-06),

6. 10976317 - Systematic discovery, maturation and extension of peptide binders to proteins (2021-04-13),

7. 10947272 - BACE1 inhibitor peptides (2021-03-16),

8. 10788495 - System and method for identification and characterization of transglutaminase species (2020-09-29),

9. 10393751 - Specific peptide binders to proteins identified via systematic discovery, maturation and extension process (2019-08-27),

10. 10161938 - Systematic discovery, maturation and extension of peptide binders to proteins (2018-12-25),

11. 10006915 - System and method for identification and characterization of transglutaminase species (2018-06-26),

12. 9133503 - Kits for detection of nucleic acids (2015-09-15),

13. 9096893 - Methods for analysis of nucleic acid molecules during amplification reactions (2015-08-04),

14. 8609336 - Detection of small nucleic acids (2013-12-17),

15. 8354232 - T-structure invasive cleavage assays, consistent nucleic acid dispensing, and low level target nucleic acid detection (2013-01-15),

Title: Victor I. Lyamichev: Pioneer in Peptide Technology and Transglutaminase Research

Introduction: Victor I. Lyamichev is a distinguished inventor based in Madison, WI, known for his significant contributions to the fields of biotechnology and molecular biology. With an impressive portfolio of 96 patents, his work has paved the way for innovations in peptide technology and enzyme research.

Latest Patents: Among his recent inventions are two notable patents that showcase his expertise. The first patent involves MHC-bound peptide arrays and methods of use thereof. This invention reveals compositions featuring a peptide as an integral component of a major histocompatibility complex (MHC) that is synthesized on a surface and linked at its C-terminus. The potential applications of these compositions can greatly enhance our understanding of peptide interactions and immune responses. The second patent details a system and method for the identification and characterization of transglutaminase species. This innovation not only describes transglutaminase enzymes and their ability to form isopeptide bonds but also introduces substrates that are more stable and resistant to protease degradation, offering new possibilities in biochemistry and therapeutic development.

Career Highlights: Throughout his career, Victor has worked with prominent companies such as Third Wave Technologies, Inc. and Roche Sequencing Solutions, Inc. His tenure in these organizations has facilitated transformative advancements in genomic and proteomic technologies, amplifying his influence within the scientific community.

Collaborations: Victor I. Lyamichev has collaborated with notable colleagues like Jeff G. Hall and James E. Dahlberg. These collaborations have spurred groundbreaking research and innovations that continue to impact various scientific fields.

Conclusion: Victor I. Lyamichev’s contributions underscore the vital role of inventors in driving technological advancements. His prowess in peptide technology and transglutaminase research not only highlights his status as an innovator but also showcases the profound impact of his inventions on the medical and scientific landscapes. As he continues to explore new frontiers in biotechnology, the scientific community eagerly anticipates the outcomes of his future endeavors.

Profile summary based on public USPTO records.